NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

Ultraz2,

You are not at all naive in believing that this DC therapy "should be" approved. At the very least it's adjuvent benefit has been very well established by evidence from outside of this trial. The evidence within this trial suggests benefit within multiple situations ie methylated and unmethylated MGMT status and mesenchymal subtype is known to respond as well even though this trial does not separately test for this as far as we know. We do not know if an improved product is being tested for equivalency or even superiority with the last patients enrolled but this might also be happening.

GBM patients need better options now and I hope interest from Right To Try builds rapidly for whatever was used in Kat's Cure. European patient interest is high and patient demand can push treatments forward very quickly in some situations. Naive? Not at all! Hopeful that common sense prevails? Absolutely!!! Best wishes.